Comparison of the incidence of febrile neutropenia in obese and normal weight breast cancer patients receiving myelosuppressive chemotherapy and prophylactic pegfilgrastim

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
Jennifer M CollinsTrevor N Christ

Abstract

Common breast cancer chemotherapy regimens are associated with a risk of febrile neutropenia, so prophylactic colony-stimulating factors are incorporated for high-risk patients. Filgrastim utilizes weight-based dosing; however, its sustained-release formulation utilizes fixed dosing. The purpose of this study is to determine whether obese breast cancer patients who receive pegfilgrastim are at increased risk of developing febrile neutropenia. This study is a single-center, retrospective chart review. Breast cancer patients were categorized as normal weight (body mass index < 30), overweight (body mass index 30-39), or obese (body mass index ≥ 40). A total of 442 eligible patients were identified between 1 July 2012 and 19 May 2016. Twenty-eight were included in the obese group. Twenty-eight patients from each non-obese group were randomly selected to make up the overweight and normal weight groups. Incidence of febrile neutropenia was 1, 2, and 2 of 28 in the normal weight, overweight, and obese research groups, respectively. Increased use of antibiotics was observed in the obese group as compared to the normal and overweight groups (2, 1, 1, respectively; p = 0.0005). Median number of days on antibiotics was statistically sign...Continue Reading

References

Dec 19, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M D GreenUNKNOWN International Pegfilgrastim 749 Study Group
Apr 5, 2011·Clinical Pharmacokinetics·Bing-Bing Yang, Anna Kido
Apr 5, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jennifer J GriggsUNKNOWN American Society of Clinical Oncology
Mar 4, 2015·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Norikazu MasudaKazuo Tamura

❮ Previous
Next ❯

Citations

Oct 27, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Olivia M KimNatalie S Callander
Apr 27, 2021·The Breast : Official Journal of the European Society of Mastology·Mark ClemonsUNKNOWN REThinking Clinical Trials (REaCT) investigators
Aug 6, 2021·Frontiers in Oncology·Chongru ZhaoYiping Wu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.